<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00590889</url>
  </required_header>
  <id_info>
    <org_study_id>979</org_study_id>
    <nct_id>NCT00590889</nct_id>
  </id_info>
  <brief_title>Artificial Valve Endocarditis Reduction Trial</brief_title>
  <acronym>AVERT</acronym>
  <official_title>Artificial Valve Endocarditis Reduction Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether the Silzone coated sewing cuff reduces
      the incidence of prosthetic valve endocarditis (PVE).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to investigate whether the Silzone coated sewing cuff reduces
      the incidence of prosthetic valve endocarditis. The null and alternative hypotheses of this
      study are:

        -  Ho: Patients receiving SJM Masters Series valves with Silzone coating will have an equal
           incidence of PVE when compared to those receiving the conventional cuff.

        -  Ha: Patients receiving SJM Masters Series valves with Silzone coating will have a
           reduced incidence of PVE when compared to those receiving the conventional cuff.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    A post-PMA begun in 1998; enrollment halted in 2000 due to an anomaly in one study arm. The
    protocol required annual study visits after 2000.
  </why_stopped>
  <start_date>July 1998</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Prosthetic Valve Endocarditis Comparing Conventional Valves to Silzone™ Coated Valves.</measure>
    <time_frame>1 year</time_frame>
    <description>Patient response to treatment with the Silzone™ treated valve will be evaluated based upon the incidence of early and late PVE (prosthetic valve endocarditis) in the treatment group vs. the control group.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">807</enrollment>
  <condition>Aortic Valve Disease</condition>
  <condition>Mitral Valve Disease</condition>
  <condition>Endocarditis</condition>
  <arm_group>
    <arm_group_label>St. Jude Medical (SJM) Conventional</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>St. Jude Medical (SJM) Standard Masters Series Mechanical Heart Valve with Conventional Cuff</description>
  </arm_group>
  <arm_group>
    <arm_group_label>St. Jude Medical (SJM) Silzone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>St. Jude Medical (SJM) Masters Series Mechanical Heart Valve with Silzone Coating</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Artificial Mechanical Heart Valve</intervention_name>
    <description>Both arms used market released mechanical heart valves in accordance with approved labeling</description>
    <arm_group_label>St. Jude Medical (SJM) Conventional</arm_group_label>
    <arm_group_label>St. Jude Medical (SJM) Silzone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient requires an isolated mitral, isolated aortic, or double (aortic and
             mitral) valve replacement

          -  The patient is a candidate to receive an SJM (St. Jude Medical) Masters Series
             valve(s) with either the conventional cuff or the cuff with Silzone coating

          -  The patient (or legal guardian) has signed a study-specific consent form agreeing to
             the randomization, data collection, and follow-up requirements

        Exclusion Criteria:

          -  The patient has a medical condition which contraindicates implantation of the SJM
             Masters Series with Silzone coating

          -  The patient already has a prosthetic valve other than the valve being replaced at this
             time

          -  The patient requires a tricuspid valve replacement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Florida Heart Group</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Womens Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sisters of Providence Health System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Heart Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LDS Hospital</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta Hospital</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital G. Et R. Laënnec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutches Herzzentrum Berlin</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fond Ne Centro S. Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Antonius Ziekenhuis</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Regional-Service de Cardiologie</name>
      <address>
        <city>Sion</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Schaff H, Carrel T, Steckelberg JM, Grunkemeier GL, Holubkov R. Artificial Valve Endocarditis Reduction Trial (AVERT): protocol of a multicenter randomized trial. J Heart Valve Dis. 1999 Mar;8(2):131-9.</citation>
    <PMID>10224570</PMID>
  </reference>
  <results_reference>
    <citation>Dávila-Román VG, Waggoner AD, Kennard ED, Holubkov R, Jamieson WR, Englberger L, Carrel TP, Schaff HV; Artificial Valve Endocarditis Reduction Trial echocardiography study. Prevalence and severity of paravalvular regurgitation in the Artificial Valve Endocarditis Reduction Trial (AVERT) echocardiography study. J Am Coll Cardiol. 2004 Oct 6;44(7):1467-72.</citation>
    <PMID>15464329</PMID>
  </results_reference>
  <results_reference>
    <citation>Schaff HV, Carrel TP, Jamieson WR, Jones KW, Rufilanchas JJ, Cooley DA, Hetzer R, Stumpe F, Duveau D, Moseley P, van Boven WJ, Grunkemeier GL, Kennard ED, Holubkov R; Artificial Valve Endocarditis Reduction Trial. Paravalvular leak and other events in silzone-coated mechanical heart valves: a report from AVERT. Ann Thorac Surg. 2002 Mar;73(3):785-92.</citation>
    <PMID>11899956</PMID>
  </results_reference>
  <results_reference>
    <citation>Englberger L, Carrel T, Schaff HV, Kennard ED, Holubkov R; AVERT Investigators. Differences in heart valve procedures between North American and European centers: a report from the Artificial Valve Endocarditis Reduction Trial (AVERT). J Heart Valve Dis. 2001 Sep;10(5):562-71.</citation>
    <PMID>11603594</PMID>
  </results_reference>
  <results_reference>
    <citation>Englberger L, Schaff HV, Jamieson WR, Kennard ED, Im KA, Holubkov R, Carrel TP; AVERT Investigators. Importance of implant technique on risk of major paravalvular leak (PVL) after St. Jude mechanical heart valve replacement: a report from the Artificial Valve Endocarditis Reduction Trial (AVERT). Eur J Cardiothorac Surg. 2005 Dec;28(6):838-43. Epub 2005 Nov 7.</citation>
    <PMID>16275007</PMID>
  </results_reference>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2007</study_first_submitted>
  <study_first_submitted_qc>January 10, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2008</study_first_posted>
  <results_first_submitted>June 22, 2015</results_first_submitted>
  <results_first_submitted_qc>November 18, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 22, 2015</results_first_posted>
  <last_update_submitted>November 18, 2015</last_update_submitted>
  <last_update_submitted_qc>November 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 22, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>artificial heart valve</keyword>
  <keyword>mitral heart valve</keyword>
  <keyword>aortic heart valve</keyword>
  <keyword>endocarditis</keyword>
  <keyword>Aortic valve disease requiring replacement</keyword>
  <keyword>Mitral valve disease requiring replacement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Heart Defects, Congenital</mesh_term>
    <mesh_term>Heart Valve Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>SJM Conventional</title>
          <description>SJM Standard Masters Series Mechanical Heart Valve with Conventional Cuff
Artificial Mechanical Heart Valve: Both arms used market released mechanical heart valves in accordance with approved labeling</description>
        </group>
        <group group_id="P2">
          <title>SJM Silzone</title>
          <description>SJM Masters Series Mechanical Heart Valve with Silzone Coating
Artificial Mechanical Heart Valve: Both arms used market released mechanical heart valves in accordance with approved labeling</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="404"/>
                <participants group_id="P2" count="403"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="118"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="286"/>
                <participants group_id="P2" count="299"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>1 subject age is missing</population>
      <group_list>
        <group group_id="B1">
          <title>SJM Conventional</title>
          <description>SJM Standard Masters Series Mechanical Heart Valve with Conventional Cuff
Artificial Mechanical Heart Valve: Both arms used market released mechanical heart valves in accordance with approved labeling</description>
        </group>
        <group group_id="B2">
          <title>SJM Silzone</title>
          <description>SJM Masters Series Mechanical Heart Valve with Silzone Coating
Artificial Mechanical Heart Valve: Both arms used market released mechanical heart valves in accordance with approved labeling</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="404"/>
            <count group_id="B2" value="403"/>
            <count group_id="B3" value="807"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>We are missing 1 person's age in the Conventional group which would make the total 404</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="244"/>
                    <measurement group_id="B2" value="218"/>
                    <measurement group_id="B3" value="462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159"/>
                    <measurement group_id="B2" value="185"/>
                    <measurement group_id="B3" value="344"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="168"/>
                    <measurement group_id="B2" value="165"/>
                    <measurement group_id="B3" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="236"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Prosthetic Valve Endocarditis Comparing Conventional Valves to Silzone™ Coated Valves.</title>
        <description>Patient response to treatment with the Silzone™ treated valve will be evaluated based upon the incidence of early and late PVE (prosthetic valve endocarditis) in the treatment group vs. the control group.</description>
        <time_frame>1 year</time_frame>
        <population>subjects randomized into the study</population>
        <group_list>
          <group group_id="O1">
            <title>SJM Conventional</title>
            <description>SJM Standard Masters Series Mechanical Heart Valve with Conventional Cuff
Artificial Mechanical Heart Valve: Both arms used market released mechanical heart valves in accordance with approved labeling</description>
          </group>
          <group group_id="O2">
            <title>SJM Silzone</title>
            <description>SJM Masters Series Mechanical Heart Valve with Silzone Coating
Artificial Mechanical Heart Valve: Both arms used market released mechanical heart valves in accordance with approved labeling</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Prosthetic Valve Endocarditis Comparing Conventional Valves to Silzone™ Coated Valves.</title>
          <description>Patient response to treatment with the Silzone™ treated valve will be evaluated based upon the incidence of early and late PVE (prosthetic valve endocarditis) in the treatment group vs. the control group.</description>
          <population>subjects randomized into the study</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="404"/>
                <count group_id="O2" value="403"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adverse Events for the Conventional Group</title>
          <description>These patients received a conventional heart valve.</description>
        </group>
        <group group_id="E2">
          <title>Adverse Events for the Silzone™ Group</title>
          <description>These patients received the Silzone™ treated heart valve.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>endocarditis</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="261" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Explant due to PV (para-valvular) leak</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="404"/>
                <counts group_id="E2" events="16" subjects_affected="16" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>All reported explants</sub_title>
                <counts group_id="E1" events="11" subjects_affected="11" subjects_at_risk="404"/>
                <counts group_id="E2" events="27" subjects_affected="27" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>All reported explants/repairs</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="404"/>
                <counts group_id="E2" events="33" subjects_affected="33" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Major PV (Para-Valvular) leak</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="404"/>
                <counts group_id="E2" events="19" subjects_affected="19" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Stroke/RIND</sub_title>
                <counts group_id="E1" events="27" subjects_affected="27" subjects_at_risk="404"/>
                <counts group_id="E2" events="26" subjects_affected="26" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>All Cause Mortality</sub_title>
                <counts group_id="E1" events="130" subjects_affected="130" subjects_at_risk="404"/>
                <counts group_id="E2" events="140" subjects_affected="140" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>endocarditis</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="404"/>
                <counts group_id="E2" subjects_affected="118" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Confirmed TE</sub_title>
                <counts group_id="E1" events="61" subjects_affected="61" subjects_at_risk="404"/>
                <counts group_id="E2" events="59" subjects_affected="59" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Confirmed TE without TIA</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="404"/>
                <counts group_id="E2" events="32" subjects_affected="32" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Confimred TE Stroke</sub_title>
                <counts group_id="E1" events="18" subjects_affected="18" subjects_at_risk="404"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="403"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="404"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="403"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was terminated early. No final report was created.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Heidi Hinrichs, VP of Clinical Study Management, St. Jude Medical</name_or_title>
      <organization>St.Jude Medical</organization>
      <email>hhinrichs@sjm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

